Trial Profile

Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs B 001 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors Shanghai Pharmaceuticals Holding

Most Recent Events

11 Nov 2021 Status changed from recruiting to completed.
29 Apr 2020 Planned End Date changed from 18 Feb 2020 to 28 Feb 2021.
29 Apr 2020 Planned primary completion date changed from 7 Jan 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com